RAS- Targeted Drug Discovery Europe Summit

Memo

After three decades of trial and error to target the driver of 30% of all diagnosed cancers, scientists are finally making meaningful clinical progression to target the cancer master switch, the RAS family of proteins. The RAS- Targeted Drug Discovery Summit Europe is the only industry and translational focused platform dedicated to bringing you innovative anti-RAS drug discovery science, capturing the most pioneering data, thought-provoking insights and practical lessons learned, enabling you to maximise the clinical therapeutic window of your anti-RAS candidate. Uniting the leading minds from large pharma, biotech and academia, this summit will help you advance novel target site discovery, improve drug-like properties and accelerate the translation of potent and mutation-specific RAS targeted therapeutic strategies into human clinical trials. With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting the RAS family of proteins, join the RAS- Targeted Drug Discovery Summit Europe to gain first-hand insights on the challenges and strategies to robustly translate promising anti-RAS therapies into the clinic. URLs: Tickets https://go.evvnt.com/533448-1?pid=5569,Brochure https://go.evvnt.com/533448-2?pid=5569,Inquiries https://go.evvnt.com/533448-4?pid=5569. Prices:Industry: Conference + Workshop: EUR 3098.00,Industry: Conference Only: EUR 2699.00,Industry: Workshop Only: EUR 499.00,Academic: Conference + Workshop: EUR 2598.00,Academic: Conference Only: EUR 2299.00,Academic: Workshop Only: EUR 399.00. Speakers: Julian Downward, Francis Crick Institute, Mariano Barbacid, CNIO (Spanish National Cancer Research Center), Darryl McConnell, Boehringer Ingelheim, Dwight V. Nissley, Frederick National Laboratory for Cancer Research, Laurent Debussche, Sanofi RandD, Steve Kelsey, Revolution Medicines, Stig Hansen, Carmot Therapeutics, Grahame Mckenzie, PhoreMost, Juan J. Perez, Allinky Biopharma, Peter DeMuth, Elicio Therapeutics, Sreesha P. Srinivasa, Oblique Therapeutics, Steven M. Fruchtman, Onconova Therapeutics, Roman Hillig, Bayer, Michael Gmachl, Boehringer Ingelheim, Sara Mainardi, Netherlands Cancer Institute. Time: 8:00 am to 5:00 pm. Venue details: Hilton Vienna Plaza, 11 Schottenring, Wien, 1010, Austria.